Psilocybin has pulled ahead in efforts to commercialize psychedelic medicine in the United States, with the Food and Drug Administration moving up its review of a Compass Pathways treatment by nine to 12 months, the applicant said. Compass hopes to receive approval before the end of the year. The drug